La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Icosavax Bilan de santé

Santé financière contrôle des critères 6/6

Icosavax possède un total de capitaux propres de $232.4M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $251.3M et de $18.9M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$229.21m
Fonds propres	US$232.38m
Total du passif	US$18.92m
Total des actifs	US$251.30m

Mises à jour récentes de la santé financière

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Recent updates

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Jul 04

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Mar 10

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Oct 18

Icosavax GAAP EPS of -$0.57

Aug 15

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de ICVX ( $235.3M ) dépassent ses passifs à court terme ( $13.0M ).

Passif à long terme: Les actifs à court terme de ICVX ( $235.3M ) dépassent ses passifs à long terme ( $5.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: ICVX est sans dette.

Réduire la dette: ICVX n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: ICVX dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: ICVX dispose d'une marge de trésorerie suffisante pour 1.9 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 51.6 % chaque année.

Icosavax Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Icosavax Files Form 15

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Recent updates

Icosavax Files Form 15

Icosavax, Inc.(NasdaqGS:ICVX) dropped from NASDAQ Composite Index

Icosavax's Shares to be Delisted from the Nasdaq Stock Market

AstraZeneca PLC (LSE:AZN) completed the acquisition of Icosavax, Inc. (NasdaqGS:ICVX) from RA Capital Management, L.P., Qiming U.S. Healthcare Fund II, L.P., managed by Qiming Weichuang Venture Capital Management (Shanghai) Company Limited and others.

President exercised options and sold US$214k worth of stock

President exercised options to buy US$1.5m worth of stock.

Chief Medical Officer notifies of intention to sell stock

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target decreased by 12% to US$21.35

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Icosavax, Inc. (NasdaqGS:ICVX) for $760 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

President notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Treasurer & Chief Business Officer notifies of intention to sell stock

Price target increased by 14% to US$23.51

Icosavax, Inc. Announces Positive Topline Interim Results from Its Phase 1 Clinical Trial of Ivx-A12 Against Respiratory Syncytial Virus (Rsv) and Human Metapneumovirus (hMPV) in Older Adults

Chief Scientific Officer notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 14% to US$20.69

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

President notifies of intention to sell stock

Icosavax, Inc. Appoints Jennifer Raymond as Senior Vice President, Technical Operations

President notifies of intention to sell stock

Chief Scientific Officer recently sold US$219k worth of stock

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.30 loss in 3Q 2021)

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax, Inc. Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Icosavax GAAP EPS of -$0.57

Chief Scientific Officer notifies of intention to sell stock

Icosavax Announces Results from Ivx-411 Drug Product Investigation and Outlines Additional Corporate Milestones

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Icosavax, Inc. Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

Icosavax, Inc.(NasdaqGS:ICVX) dropped from Russell 2000 Growth Index

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

High number of new directors

Icosavax, Inc., Annual General Meeting, Jun 10, 2022

Independent Chair recently bought US$300k worth of stock

Consensus revenue estimates increase by 36%

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Treasurer & Chief Business Officer notifies of intention to sell stock

Insider exercised options to buy US$1.2m worth of stock.

Chief Medical Officer exercised options to buy US$897k worth of stock.

President exercised options and sold US$91k worth of stock

High number of new and inexperienced directors

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Icosavax, Inc. Announces the Initiation of A Phase 1/1B Clinical Trial of IVX-121

Independent Chairman of the Board Tadataka Yamada has left the company

Independent Chairman of the Board Tadataka Yamada has left the company

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines